Syncona Limited

BACT

GG00B8P59C08

Investment Holding Companies

Market Closed - London S.E. Other stock markets 11:35:14 2024-04-26 am EDT			5-day change	1st Jan Change
128.4 ^GBX	+1.10%		+5.77%	+4.05%

Apr. 11	Syncona agrees to sell stake in investee company for GBP7.4 million	AN
Apr. 11	Syncona to Sell Stake in Portfolio Company to Century Therapeutics	MT

Syncona notes FDA acceptance of Autolus's BLA for obe-cel

January 22, 2024 at 07:20 am EST

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Syncona has an 18% stake in Autolus.

Current stock price: 117.05 pence, down 0.3% on Monday

12-month change: down 31%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	SYNCONA LIMITED	128.4 GBX	+1.10%	+5.77%	1.04B
	AUTOLUS THERAPEUTICS PLC	4 USD	-1.96%	-11.50%	1.06B

Latest news about Syncona Limited

Syncona agrees to sell stake in investee company for GBP7.4 million	Apr. 11	AN
Syncona to Sell Stake in Portfolio Company to Century Therapeutics	Apr. 11	MT
Syncona notes investee Achilles's annual loss narrows	Apr. 04	AN
Syncona portfolio company Autolus posts widened loss for 2023	Mar. 14	AN
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	Feb. 20	MT
Freeline shareholders approve Syncona acquisition	Feb. 12	AN
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona	Feb. 12	MT
Syncona portfolio strengthens in third quarter thanks to Autolus	Feb. 08	AN
Syncona's Fiscal Q3 NAV Declines	Feb. 08	MT
Tranche Update on Syncona Limited's Equity Buyback Plan announced on September 29, 2023.	Feb. 08	CI
Syncona notes FDA acceptance of Autolus's BLA for obe-cel	Jan. 22	AN
Syncona says Freeline trial for Gaucher disease treatment positive	Jan. 19	AN
Syncona notes Beacon's "encouraging" AGTC-501 trial data	Dec. 04	AN
Molten Ventures completes raise; Saietta proposes one	Nov. 27	AN
Sector Update: Health Care Stocks Advance Late Afternoon	Nov. 22	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Nov. 22	MT
FTSE 100 Closes Down 0.17% After Autumn Statement	Nov. 22	DJ
Syncona agrees to buyout deal with Freeline Therapeutics	Nov. 22	AN
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	Nov. 22	MT
Sector Update: Health Care	Nov. 22	MT
Syncona to Take Over Freeline Therapeutics	Nov. 22	MT
Freeline Therapeutics to be Acquired by Syncona for $28.3 Million	Nov. 22	MT
Syncona reports declining asset value as investment head steps down	Nov. 16	AN
Transcript : Syncona Limited, Q2 2024 Earnings Call, Nov 16, 2023	Nov. 16
Syncona Swings to Fiscal H1 Loss; Invest Income Falls	Nov. 16	MT

Chart Syncona Limited

Duration

Period

More charts

Company Profile

Syncona Limited is a Guernsey-based closed-ended investment company. The Companyâs investment objective is to achieve superior long-term capital appreciation from its investments. It seeks to achieve returns over the long term. It focuses on creating, building and scaling companies around science to create a diversified portfolio of 20-25 global healthcare businesses, across development stage and therapeutic areas. It focuses on developing treatments for patients by working in close partnership with academic founders and management teams. The Company makes its life science investments through Syncona Holdings Limited, a subsidiary of the Company. It maintains its capital pool through Syncona Investments LP Incorporated (the Partnership) in which the Company is the sole limited partner. The general partner of the Partnership is Syncona GP Limited (the General Partner), a wholly owned subsidiary of the Company. Syncona Investment Management Limited is its alternative investment manager.

Sector

Investment Holding Companies

Calendar

2024-06-20 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.284 GBP

Average target price

2.453 GBP

Spread / Average Target

+91.07%

Consensus

Sector Other Holding Companies

	1st Jan change	Capi.
SYNCONA LIMITED	+4.05%	1.04B
INVESTOR AB	+16.54%	75.59B
KOÇ HOLDING	+53.03%	16.95B
INVESTMENT AB LATOUR	+3.20%	15.78B
AB INDUSTRIVÄRDEN	+7.21%	13.87B
L E LUNDBERGFÖRETAGEN AB	-0.77%	12.3B
HAL TRUST	+9.67%	12.04B
BAJAJ HOLDINGS & INVESTMENT LIMITED	+6.24%	10.88B
MERITZ FINANCIAL GROUP INC.	+34.86%	10.17B
GROUPE BRUXELLES LAMBERT SA	-1.71%	9.7B

Other Holding Companies

Syncona Limited

Equities

BACT

GG00B8P59C08

Investment Holding Companies

Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Stocks mentioned in the article

Latest news about Syncona Limited

Chart Syncona Limited

Company Profile

Income Statement Evolution

Analysts' Consensus

Sector Other Holding Companies